Cargando…

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)

Nanovaccine In article number 2203298, Baorui Liu, Jia Wei, and co‐workers prepare a personalized neoantigen nanovaccine (PNVAC) which spatially displays impressively enhanced lymph nodes trafficking capacity, and functionally induces more mature dendritic cells (DCs), neoantigen‐specific T cells, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qin, Chu, Yanhong, Shao, Jie, Qian, Hanqing, Yang, Ju, Sha, Huizi, Cen, Lanqi, Tian, Manman, Xu, Qiuping, Chen, Fangjun, Yang, Yang, Wang, Weifeng, Wang, Kai, Yu, Lixia, Wei, Jia, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811463/
http://dx.doi.org/10.1002/advs.202370001
_version_ 1784863538810978304
author Liu, Qin
Chu, Yanhong
Shao, Jie
Qian, Hanqing
Yang, Ju
Sha, Huizi
Cen, Lanqi
Tian, Manman
Xu, Qiuping
Chen, Fangjun
Yang, Yang
Wang, Weifeng
Wang, Kai
Yu, Lixia
Wei, Jia
Liu, Baorui
author_facet Liu, Qin
Chu, Yanhong
Shao, Jie
Qian, Hanqing
Yang, Ju
Sha, Huizi
Cen, Lanqi
Tian, Manman
Xu, Qiuping
Chen, Fangjun
Yang, Yang
Wang, Weifeng
Wang, Kai
Yu, Lixia
Wei, Jia
Liu, Baorui
author_sort Liu, Qin
collection PubMed
description Nanovaccine In article number 2203298, Baorui Liu, Jia Wei, and co‐workers prepare a personalized neoantigen nanovaccine (PNVAC) which spatially displays impressively enhanced lymph nodes trafficking capacity, and functionally induces more mature dendritic cells (DCs), neoantigen‐specific T cells, and memory effector T cells. The PNVAC demonstrates superior protective efficacy against advanced gastric cancer recurrence and longer survival in preclinical studies and a phase I clinical trial. [Image: see text]
format Online
Article
Text
id pubmed-9811463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98114632023-01-05 Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023) Liu, Qin Chu, Yanhong Shao, Jie Qian, Hanqing Yang, Ju Sha, Huizi Cen, Lanqi Tian, Manman Xu, Qiuping Chen, Fangjun Yang, Yang Wang, Weifeng Wang, Kai Yu, Lixia Wei, Jia Liu, Baorui Adv Sci (Weinh) Cover Picture Nanovaccine In article number 2203298, Baorui Liu, Jia Wei, and co‐workers prepare a personalized neoantigen nanovaccine (PNVAC) which spatially displays impressively enhanced lymph nodes trafficking capacity, and functionally induces more mature dendritic cells (DCs), neoantigen‐specific T cells, and memory effector T cells. The PNVAC demonstrates superior protective efficacy against advanced gastric cancer recurrence and longer survival in preclinical studies and a phase I clinical trial. [Image: see text] John Wiley and Sons Inc. 2023-01-04 /pmc/articles/PMC9811463/ http://dx.doi.org/10.1002/advs.202370001 Text en © 2023 Wiley‐VCH GmbH https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Cover Picture
Liu, Qin
Chu, Yanhong
Shao, Jie
Qian, Hanqing
Yang, Ju
Sha, Huizi
Cen, Lanqi
Tian, Manman
Xu, Qiuping
Chen, Fangjun
Yang, Yang
Wang, Weifeng
Wang, Kai
Yu, Lixia
Wei, Jia
Liu, Baorui
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
title Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
title_full Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
title_fullStr Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
title_full_unstemmed Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
title_short Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
title_sort benefits of an immunogenic personalized neoantigen nanovaccine in patients with high‐risk gastric/gastroesophageal junction cancer (adv. sci. 1/2023)
topic Cover Picture
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811463/
http://dx.doi.org/10.1002/advs.202370001
work_keys_str_mv AT liuqin benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT chuyanhong benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT shaojie benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT qianhanqing benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT yangju benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT shahuizi benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT cenlanqi benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT tianmanman benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT xuqiuping benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT chenfangjun benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT yangyang benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT wangweifeng benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT wangkai benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT yulixia benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT weijia benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023
AT liubaorui benefitsofanimmunogenicpersonalizedneoantigennanovaccineinpatientswithhighriskgastricgastroesophagealjunctioncanceradvsci12023